Revised international staging system for multiple myeloma: A report from international myeloma working group

Journal of Clinical Oncology

Volumn 33, Issue 26, 2015, Pages 2863-2869

  Palumbo, Antonio ^a   Avet Loiseau, Hervé ^f   Oliva, Stefania ^a   Lokhorst, Henk M ⁱ   Goldschmidt, Hartmut ^k   Rosinol, Laura ^l   Richardson, Paul ^o   Caltagirone, Simona ^a   Lahuerta, Juan José ^m   Facon, Thierry ^g   Bringhen, Sara ^a   Gay, Francesca ^a   Attal, Michel ^f   Passera, Roberto ^a   Spencer, Andrew ^u   Offidani, Massimo ^b   Kumar, Shaji ^p   Musto, Pellegrino ^c   Lonial, Sagar ^q   Petrucci, Maria T ^d   Orlowski, Robert Z ^r   Zamagni, Elena ^e   Morgan, Gareth ^s   Dimopoulos, Meletios A ^v   Durie, Brian G M ^t   Anderson, Kenneth C ^o   Sonneveld, Pieter ^j   Miguel, Jésus San ⁿ   Cavo, Michele ^e   Rajkumar, S Vincent ^p   Moreau, Philippe ^h   more..

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f INSTITUT CLAUDIUS REGAUD   (France)

^g UNIV LILLE   (France)

^h HÔTEL DIEU   (France)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^l HOSPITAL CLÍNIC   (Spain)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ UNIVERSITY OF NAVARRA   (Spain)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p MAYO CLINIC   (United States)

^q EMORY UNIVERSITY   (United States)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^s UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^t CEDARS SINAI MEDICAL CENTER   (United States)

^u ALFRED HEALTH   (Australia)

^v UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; SERUM ALBUMIN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERPHASE FLUORESCENT IN SITU HYBRIDIZATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PURIFICATION; ADOLESCENT; BLOOD; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING;

EID: 84951020021     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.2267     Document Type: Article

References (29)

1. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 364:1046-1060, 2011
2. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
3. Ross FM, Avet-Loiseau H, Ameye G, et al: Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97:1272-1277, 2012
4. Fonseca R, Bergsagel PL, Drach J, et al: International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review. Leukemia 23:2210-2221, 2009
5. Dimopoulos MA, Barlogie B, Smith TL, et al: High serum lactate dehydrogenase level as a marker for drug resistence and short survival in multiple myeloma. Ann Intern Med 115:931-935, 1991
6. Terpos E, Katodritou E, Roussou M, et al: High serum lactate dehydrogenase adds prognostic value to the international staging system even in the era of novel agents. Eur J Haematol 85:114-119, 2010
7. Anagnostopoulos A, Gika D, Symeonidis A, et al: Multiple myeloma in elderly patients: Prognostic factors and outcome. Eur J Haematol 75:370-375, 2005
8. Barlogie B, Bolejack V, Schell M, et al: Prognostic factor analysis of myeloma survival with intergroup trial S9321 (INT 0141): Examining whether different variables govern different time segments of survival. Ann Hematol 90:423-428, 2011
9. Barlogie B, Smallwood L, Smith T, et al: High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med 110:521-525, 1989
10. Neben K, Jauch A, Bertsch U, et al: Combining information regarding chromosomal aberrations t(4;14) and del (17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95:1150-1157, 2010
11. Boyd KD, Ross FM, Chiecchio L, et al: A novel prognostic model in myeloma based on cosegregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26:349-355, 2012
12. Avet-Loiseau H, Durie BG, Cavo M, et al: Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project. Leukemia 27:711-717, 2013
13. Moreau P, Cavo M, Sonneveld P, et al: Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem cell transplantation at high-risk of early MM progressionrelated death. J Clin Oncol 32:2173-2180, 2014
14. Bringhen S, Petrucci MT, Larocca A, et al: Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: A multicenter, phase 2 study. Blood 124: 63-69, 2014
15. Magarotto V, Bringhen S, Musto P, et al: Doublet vs triplet lenalidomide-containing regimens in newly diagnosed myeloma patients, younger or older than 75 years: Subgroup analysis of a phase III study. Blood 124:2110, 2014 (abstr)
16. Palumbo A, Gay F, Spencer A, et al: A phase III study of ASCT vs cyclophosphamidelenalidomide-dexamethasone and lenalidomideprednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients. Blood 122:763, 2013 (abstr)
17. Palumbo A, Cavallo F, Gay F: Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371:895-905, 2014
18. Gay F, Magarotto V, Crippa C, et al: Bortezomib induction, reduced-intensity transplantation and lenalidomide consolidation-maintenance for myeloma: Updated results. Blood 122:1376-1383, 2013
19. Palumbo A, Bringhen S, Larocca A, et al: Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival. J Clin Oncol 32: 634-640, 2014
20. Larocca A, Cavallo F, Magarotto V, et al: Reduced dose-intensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosphamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of age. Blood 122:539, 2013 (abstr)
21. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30:2946-2955, 2012
22. Cavo M, Tacchetti P, Patriarca F, et al: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 376:2075-2085, 2010
23. Rosiñol L, Oriol A, Teruel AI, et al: Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pre transplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study. Blood 120:1589-1596, 2012
24. Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple-myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621-4629, 2010
25. Eo S-H, Hong S-M, Cho HY: K-adaptive partitioning for survival data: The Kaps add-on package for R. J Stat Software (in press)
26. Breiman Leo: Classification and Regression Trees. Boca Raton, FL, Chapman & Hall/CRC, 1984
27. Shaughnessy JD Jr, Zhan F, Burington BE, et al: A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109:2276-2284, 2007
28. Kuiper R, van Vliet M, de Knegt Y, et al: Comparison of conventional, FISH and GEP prognostic factors in multiple myeloma: Introducing a novel risk stratification. Blood 122:3092, 2013 (abstr)
29. López-Corral L, Sarasquete ME, Beà S, et al: SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia 26:2521-2529, 2012